DUPIXENT is indicated in patients 6 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1
raised blood eosinophils (EOS)
and/or raised fraction of exhaled nitric oxide (FeNO)
who are inadequately controlled with high-dose (ages 12 and older) and medium-to-high dose (ages 6 to 11) inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment
An extensive clinical trial programme
ADULTS AND ADOLESCENTS:
DUPIXENT was studied in one Phase 2b and two Phase 3 clinical trials including 2,888 patients aged 12 years and older, for up to 52 weeks1
CHILDREN:
DUPIXENT was studied in a phase 3 clinical trial over a period of up to 52 weeks in children 6 – 11 years of age2
INTRODUCING THE DUPIXENT PRE-FILLED PEN
DUPIXENT can be administered with a pre-filled pen (patients aged 12 years and older only) or a pre-filled syringe (patients of all ages)1,3
Adult and adolescent trial design
Learn more about how the clinical trials have been designed.
- DUPIXENT Summary of Product Characteristics, Date accessed: April 2023.
- Bacharier LB, et al. 2021 N Engl J Med; 385(24):2230-2240. doi:10.1056/ NEJMoa2106567.
- Sanofi Data on File. MAT-IE-2000837 (v2.0). 2021.
References
MAT-XU-2204638 (v1.0) | Date of preparation: April 2023